UB Paderborn / Katalog / Suche / in CDI

Screening and Prostate-Cancer Mortality in a Randomized European Study

The New England journal of medicine, 2009-03, Vol.360 (13), p.1320-1328

2009

Link zum Volltext

Verfügbarkeit prüfen

Screening for Prostate Cancer: Results of the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer

European urology, 2013-10, Vol.64 (4), p.530-539

2013

Link zum Volltext

Verfügbarkeit prüfen

On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer

European journal of cancer (1990), 2010-11, Vol.46 (17), p.3109-3119

2010

Link zum Volltext

Verfügbarkeit prüfen

Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9 ng/ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness

The Journal of urology, 2004-06, Vol.171 (6 Pt 1), p.2245

2004

Link zum Volltext

Verfügbarkeit prüfen

hK2 and Free PSA, a Prognostic Combination in Predicting Minimal Prostate Cancer in Screen-Detected Men within the PSA Range 4–10 ng/ml

European urology, 2007-11, Vol.52 (5), p.1358-1364

2007

Link zum Volltext

Verfügbarkeit prüfen

Additional use of [−2] precursor prostate-specific antigen and “benign” PSA at diagnosis in screen-detected prostate cancer

Urology (Ridgewood, N.J.), 2005-05, Vol.65 (5), p.926-930

2005

Link zum Volltext

Verfügbarkeit prüfen

Prostate-Cancer Mortality at 11 Years of Follow-up

The New England journal of medicine, 2012-03, Vol.366 (11), p.981-990

2012

Link zum Volltext

Verfügbarkeit prüfen

Prostate cancer characteristics and prostate specific antigen changes in screening detected patients initially treated with a watchful waiting policy

The Journal of urology, 2004-12, Vol.172 (6 Pt 1), p.2193

2004

Link zum Volltext

Verfügbarkeit prüfen

Assay-specific artificial neural networks for five different PSA assays and populations with PSA 2-10 ng/ml in 4,480 men

World journal of urology, 2007-03, Vol.25 (1), p.95-103

2007

Link zum Volltext

Verfügbarkeit prüfen

The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population

The Journal of urology, 1997-06, Vol.157 (6), p.2191

1997

Link zum Volltext

Verfügbarkeit prüfen

Persistent leukocyturia and loss of renal function in a prospectively monitored cohort of HIV-infected patients treated with indinavir

Journal of acquired immune deficiency syndromes (1999), 2003-02, Vol.32 (2), p.135

2003

Link zum Volltext

Verfügbarkeit prüfen

The value of screening tests in the detection of prostate cancer. Part I: Results of a retrospective evaluation of 1726 men

Urology (Ridgewood, N.J.), 1995-12, Vol.46 (6), p.773-778

1995

Link zum Volltext

Verfügbarkeit prüfen

Rotterdam Randomized Pilot Studies of Screening for Prostate Cancer—An Overview After 10 Years

JNCI : Journal of the National Cancer Institute, 2005-05, Vol.97 (9), p.696-696

2005

Link zum Volltext

Verfügbarkeit prüfen

Comparison of Two Assays for Human Kallikrein 2

Clinical chemistry (Baltimore, Md.), 2003-02, Vol.49 (2), p.243-247

2003

Link zum Volltext

Verfügbarkeit prüfen

Technical performance and diagnostic utility of the new elecsys® neuron-specific enolase enzyme immunoassay

Clinical chemistry and laboratory medicine, 2003-01, Vol.41 (1), p.95-103

2003

Link zum Volltext

Verfügbarkeit prüfen

New developments in the standardization of total prostate-specific antigen

Clinical biochemistry, 1999-11, Vol.32 (8), p.627-634

1999

Link zum Volltext

Verfügbarkeit prüfen

Analytical issues on prostate-specific antigen in relation to prostate cancer screening

Clinical biochemistry, 1998-11, Vol.31 (8), p.633-639

1998

Link zum Volltext

Verfügbarkeit prüfen

On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer: Screening for Prostate Cancer; Lessons Learnt from the European Randomised Study of Screening for Prostate Cancer

European journal of cancer (1990), 2010, Vol.46 (17), p.3109-3119

2010

Link zum Volltext

Verfügbarkeit prüfen

The free-to-total serum prostate specific antigen ratio for staging prostate carcinoma

The Journal of urology, 1997-02, Vol.157 (2), p.544

1997

Link zum Volltext

Verfügbarkeit prüfen

The value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density

Urology (Ridgewood, N.J.), 1995-12, Vol.46 (6), p.779-784

1995

Link zum Volltext

Verfügbarkeit prüfen

On the Standardization of Total Prostate-Specific Antigen: an Exercise with Two Reference Preparations

Clinical chemistry and laboratory medicine, 1999-05, Vol.37 (5), p.545-552

1999

Link zum Volltext

Verfügbarkeit prüfen

Technical Performance and Diagnostic Utility of the New Elecsys® Neuron-Specific EnolaseEnzyme Immunoassay

Clinical chemistry and laboratory medicine, 2003-01, Vol.41 (1), p.95-103

2003

Link zum Volltext

Verfügbarkeit prüfen

Validation of a natural urinary stone data based infrared library searching system with artificial survey samples

European journal of clinical chemistry and clinical biochemistry, 1997-08, Vol.35 (8), p.625

1997

Link zum Volltext

Verfügbarkeit prüfen

Analytical evaluation of the new Prostatus PSA Free/Total assay for prostate-specific antigen as part of a screening study for prostate cancer

European journal of clinical chemistry and clinical biochemistry, 1997-02, Vol.35 (2), p.111

1997

Link zum Volltext

Verfügbarkeit prüfen

Multicentre evaluation of the Boehringer Mannheim/Hitachi 917 analysis system

Journal of automated methods & management in chemistry, 2000, Vol.22 (3), p.65-81

2000

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Screening and Prostate-Cancer Mortality in a Randomized European Study

Screening for Prostate Cancer: Results of the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer

On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer

Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9 ng/ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness

hK2 and Free PSA, a Prognostic Combination in Predicting Minimal Prostate Cancer in Screen-Detected Men within the PSA Range 4–10 ng/ml

Additional use of [−2] precursor prostate-specific antigen and “benign” PSA at diagnosis in screen-detected prostate cancer

Prostate-Cancer Mortality at 11 Years of Follow-up

Prostate cancer characteristics and prostate specific antigen changes in screening detected patients initially treated with a watchful waiting policy

Assay-specific artificial neural networks for five different PSA assays and populations with PSA 2-10 ng/ml in 4,480 men

The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population

Persistent leukocyturia and loss of renal function in a prospectively monitored cohort of HIV-infected patients treated with indinavir

The value of screening tests in the detection of prostate cancer. Part I: Results of a retrospective evaluation of 1726 men

Rotterdam Randomized Pilot Studies of Screening for Prostate Cancer—An Overview After 10 Years

Comparison of Two Assays for Human Kallikrein 2

Technical performance and diagnostic utility of the new elecsys® neuron-specific enolase enzyme immunoassay

New developments in the standardization of total prostate-specific antigen

Analytical issues on prostate-specific antigen in relation to prostate cancer screening

On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer: Screening for Prostate Cancer; Lessons Learnt from the European Randomised Study of Screening for Prostate Cancer

The free-to-total serum prostate specific antigen ratio for staging prostate carcinoma

The value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density

On the Standardization of Total Prostate-Specific Antigen: an Exercise with Two Reference Preparations

Technical Performance and Diagnostic Utility of the New Elecsys® Neuron-Specific EnolaseEnzyme Immunoassay

Validation of a natural urinary stone data based infrared library searching system with artificial survey samples

Analytical evaluation of the new Prostatus PSA Free/Total assay for prostate-specific antigen as part of a screening study for prostate cancer

Multicentre evaluation of the Boehringer Mannheim/Hitachi 917 analysis system

Suchergebnisse filtern